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Aims Tumour necrosis factor-a (TNF-a) plays a key role in the regulationof cardiac contractility. Although cardiomyocytes are
known to express the TNF-a receptors (TNFRs), the mechanism of TNF-a signal transmission is incompletely under-
stood. The aim of this study was to investigate whether the tumour suppressor Ras-association domain family protein
1 isoform A (RASSF1A) modulates TNF-a signalling in cardiomyocytes.
Methods
and results
We used RASSF1A knockout (RASSF1A2/2) mice and wild-type (WT) littermates in this study. Acute stimulation with a
low dose of TNF-a (10 mg/kg iv) increased cardiac contractility and intracellular calcium transients’ amplitude in WT
mice. In contrast, RASSF1A2/2 mice showed a blunted contractile response. Mechanistically, RASSF1A was essential
in the formation of the TNFR complex (TNFRC), where it functions as an adaptor molecule to facilitate the recruitment
of TNFR type 1-associated death domain protein and TNFR-associated factor 2 to form the TNF-a receptor complex.
In the absence of RASSF1A, signal transmission from the TNF-a receptor complex to the downstream effectors, such as
cytoplasmic phospholipase A2 and protein kinase A, was attenuated leading to the reduction in the activation of calcium
handling molecules, such as L-type Ca2+ channel and ryanodine receptors.
Conclusion Our data indicate an essential role of RASSF1A in regulating TNF-a signalling in cardiomyocytes, with RASSF1A being key
in the formation of the TNFRC and in signal transmission to the downstream targets.
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1. Introduction
Tumour necrosis factor-a (TNF-a) is a pro-inflammatory cytokine that
plays an important role in the heart, in particular, in the regulation of con-
tractility and left ventricular (LV) remodelling. Micewith cardiomyocyte-
specific overexpression of TNF-a developed dilated cardiomyopathy,
altered cardiac contractility, and abnormal intracellular calcium dynam-
ics.1 –4 TNF-a effects in the heart seem to be dose- and time-dependent.
For example, treatment of adult cardiomyocytes with TNF-a for 12 h
protects against hypoxic injury.5 Also, low dose of TNF-a treatment
induces hypertrophic growth in isolated myocytes,6 whereas acute
treatment with a low dose of TNF-a produces a positive inotropic
effect in conscious dogs.7 Moreover, TNF-a appears to produce
biphasic effects on cardiac contractility: at low concentrations, TNF-a
increases the amplitude of [Ca2+]i transients and contraction, whereas
at high concentrations TNF-a impairs electrically stimulated [Ca2+]i
transients and contraction.8,9
TNF-a is involved in a number of pathological conditions. For
example, TNF-a is one of the key mediators of systemic endotoxemia.10
Serum TNF-a level is dramatically elevated in endotoxemia and may be
important in determining cardiac contractile function in this condition.
TNF-amainly exerts its biological effects through binding to two dif-
ferent types of TNF-a receptors, TNFR1 and TNFR2, both of which are
expressed in cardiomyocytes.11 Upon binding to TNF-a, the TNFRs
recruit a number of molecules to form the TNFR complex (TNFRC),
which in turn initiates the activation of the downstream signalling
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cascade.12 Here, we discover for the first time that a Ras effector/inter-
acting protein, the Ras-association domain family protein 1 isoform A
(RASSF1A), is essential for the formation of the TNFRC in cardiomyo-
cytes. RASSF1A is a tumour suppressor molecule that in non-
cardiomyocytes regulates a number of important cellular processes
such as apoptosis, cell growth and viability, and also the cell cycle.
RASSF1A lacks enzymatic activity and it exerts its functions mainly via
interaction with and modulation of other molecules.13,14 RASSF1A is
expressed in the heart, but its involvement in the regulation of TNF-a
signalling in cardiomyocytes is unknown.
In the present study, we used a RASSF1A knockout mouse model, as
well as isolated cardiomyocytes with genetic ablation or overexpression
of RASSF1A, to demonstrate the pivotal role of this molecule in mediat-
ing the TNF-a-induced contractile response in cardiomyocytes and in
the whole heart.
2. Methods
2.1 Plasmids
The human RASSF1A cDNA was a gift of Dr Geoffrey Clark (Louisville, KY,
USA). The generation of RASSF1A deletion mutants has been described pre-
viously.15 Plasmid containing human TNFR-associated factor 2 (TRAF2)
cDNA was a gift of Dr John Kyriakis (Boston, MA, USA; Addgene plasmid
#21586).16 Plasmids containing human TNFR1 and human TNFR type
1-associated death domain protein (TRADD) were obtained from
Origene. For the NFkB activity assay, we used a luciferase construct contain-
ing four tandem repeats of NFkB-binding sites (Clontech). For RASSF1A
gene silencing, we used shRNA targeting rat RASSF1A driven by the U6 pro-
moter and shRNA containing scrambled sequence driven by the same pro-
moter was used as the control.
2.2 Generation of adenoviral constructs
Adenoviruses were generated by cloning cDNAs to the pAd/CMV/
V5-DEST vector (Invitrogen) using the Gateway system following the man-
ufacturer’s recommended methods. pENTR11 vector (Invitrogen) was used
as the shuttle system.
2.3 Animals
We used mice with systemic genetic ablation of the Rassf1a gene as
described previously.17 All animal experiments were performed on 16- to
20-week-old mice in accordance with the UK Animals (Scientific Proce-
dures) Act 1986 and were approved by the University of Manchester
Ethics Committee.
2.4 Haemodynamic analysis
In vivo haemodynamic analyses were performed as described previously.18
Briefly, mice were anaesthetized by intraperitoneal injection of tribro-
moethanol [240 mg/kg body weight (BW)] and placed on a heat pad at
378C. A 1.4-Fr pressure–volume catheter (Millar Instruments) was inserted
into the left ventricle via the right carotid artery. Pressure–volume signals
were recorded first under basal conditions and then recorded 30 min
after intravenous injection of TNF-a (10 mg/kg BW).
2.5 Isolation of mouse adult cardiomyocytes
and neonatal rat cardiomyocytes
Adult cardiomyocytes were isolated from 3- to 4-month-old wild-type
(WT) or RASSF1A2/2 mice, using methods described previously.18 Neo-
natal rat cardiomyocyteswere isolated from1- to3-day-old Sprague-Dawley
rats. Details of the isolation methods areprovided inSupplementary material
online, Methods.
2.6 Intracellular calcium transient
measurements
Isolated adult cardiomyocyteswere loaded with calcium ratiometric fluores-
cent dye (Indo-l). In order to measure the cytosolic calcium, the myocytes
were perfused with Tyrode solution and then field stimulated at a frequency
of 1 Hz. Calcium changes during myocyte contraction were recorded before
and after stimulation with either TNF-a (10 ng/mL) or isoproterenol
(100 nM) as previously described.18 To assess the involvement of cytoplas-
mic phospholipase A2 (cPLA2), we treated cardiomyocytes with cPLA2 in-
hibitor AACOCF3 (Calbiochem) at a dose of 20 mM or cPLA2 activator
peptide PLAP (Santa Cruz Biotechnology) at 1 mM. Details of calcium tran-
sientmeasurement areprovided inSupplementarymaterial online,Methods.
2.7 Data analysis
Data are presented as mean+ SEM. Statistical analyses were carried out
using the Student’s t-test, one- or two-way analysis of variance (ANOVA),
where appropriate. Values were considered significant if P, 0.05 [see Sup-
plementary material online, Methods for western blot, immunoprecipita-
tion, cPLA2, PKA, calcium–calmodulin-dependent kinase II (CaMKII), and
NFkB activity assays].
3. Results
3.1 RASSF1A2/2mice showed a blunted
contractile response following acute
treatment with a low dose of TNF-a
To assess the involvement of RASSF1A in TNF-a signalling, we injected
a low dose of TNF-a (10 mg/kg BW) intravenously in WT and
RASSF1A2/2 mice. We analysed pressure–volume loops to assess
indices of contractility (Figure 1A and B, and Table 1). There was no sig-
nificant difference in basal haemodynamic indices between WT and
RASSF1A2/2 mice. However, paired analysis between basal and
30-minpost-TNF-a infusion showed that acute TNF-a treatment signifi-
cantly increased end-systolic LV pressure and decreased end-diastolic
LV pressurewithout creating any changes in heart rate and other diastol-
ic parameters in both WT and knockout mice (Table 1). The changes in
indices of contractility (DdP/dtmax and DEes [end-systolic elastance]) in
response to TNF-a were dramatically different between WT and
RASSF1A2/2 mice. Both Ees and dP/dtmax were significantly enhanced
in WT animals (Figure 1C and D), indicating that acute treatment with a
low dose of TNF-a increased cardiac contractility, which was consistent
with previously published data.7 –9 Interestingly, RASSF1A2/2 mice
showed a blunted contractile response following treatment with the
same dose of TNF-a as indicated by DdP/dtmax and DEes (n ¼ 7–10,
P, 0.05) (Figure 1C and D). These data suggested that RASSF1A is
involved in modulating the cardiac contractile response following
TNF-a stimulation.
3.2 RASSF1Amodulates TNF-a signalling
in isolated adult cardiomyocytes
TNF-a injection in mice could affect various cell types such as macro-
phages and endothelial cells, which could trigger an immune response.
Therefore, to investigate whether RASSF1A mediates TNF-a-induced
contractile response as a direct effect on cardiomyocytes, we assessed
the effect of low-dose TNF-a treatment (10 ng/mL for 30 min) on iso-
lated adult WT and RASSF1A2/2 cardiomyocytes. Consistent with the
in vivo data, isolated adult cardiomyocytes from WT animals showed sig-
nificantly higher calcium transient amplitude in response to TNF-a
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stimulation (Figure 2A and B). However, RASSF1A2/2 cardiomyocytes
showed no significant change in calcium transient amplitude following
similar stimulation (Figure 2A and B). No changes in the calcium decay
rate were observed in both RASSF1A2/2 and WT mice (Figure 2C).
These data confirm the regulatory role of RASSF1A in cardiomyocytes
and imply that the in vivo effect described in Figure 1 was likely due to the
direct TNF-a effect on cardiomyocytes.
Next, we analysed whether RASSF1A ablation alters theb-adrenergic
pathway. Data presented in Figure 2D–F showed that there was no dif-
ference between WT and RASSF1A2/2 cardiomyocytes regarding the
change in calcium amplitude and calcium decay rate following
b-adrenergic agonist (isoproterenol) stimulation.
3.3 RASSF1A ablation alters the formation
of TNFRC in cardiomyocytes
It has been described that, following activation by TNF-a, the TNFR
recruits several molecules such as TRAF2 and TRADD to form a
TNFRC,19 a process which is essential in signal transmission to the intra-
cellular effectors. To investigate the importance of RASSF1A in the for-
mation of TNFRC, we conducted co-immunoprecipitation experiments
in adult cardiomyocytes isolated from RASSF1A2/2 mice and their WT
littermates with or without TNF-a treatment. In WT cardiomyocytes,
TNFR1 co-precipitated with both TRAF2 and TRADD and the
amount of co-precipitated proteins increased following TNF-a treat-
ment (Figure 3A and B). In contrast, there was a marked reduction in
co-immunoprecipitation between TNFR1 and TRAF2/TRADD in
RASSF1A2/2 myocytes before and after TNF-a treatment (Figure 3A
and B). The levels of TNFR1, TRADD, and TRAF2 expressions were
not different between WT and RASSF1A2/2 (see Supplementary ma-
terial online, Figure S1). These data suggest that RASSF1A might play
an essential role in the recruitment of TRADD and TRAF2 to the
TNFR and the formation of TNFRC following TNF-a stimulation.
3.4 RASSF1A interacts with components
of TNFRC
To further investigate the mechanism by which RASSF1A modulates
the formation of TNFRC, we performed experiments to determine
whether RASSF1A interacts with components of TNFRC. A previous
report has shown the association of RASSF1A with TNFR1 in the
U2OS osteosarcoma cell line.20 However, it is not known whether
RASSF1A binds to TRAF2 and TRADD and whether it links these
molecules to TNFR1 following TNF-a stimulation. We conducted
co-immunoprecipitation experiments in isolated neonatal rat cardio-
myocytes to examine the possible protein–protein interactions
Figure 1 Effect of acute TNF-a stimulation on cardiac contractility in RASSF1A2/2 and WT littermates. Representative pressure–volume loops from
(A) WT and (B) RASSF1A2/2 mice under basal conditions (blue line) and 30 min after intravenous injection with TNF-a (10 mg/kg BW) (red line). Dotted
lines represent end-systolic elastance (Ees). (C ) The change in end-systolic elastance (DEes) after TNF-a injection was measured. WT mice showed a sig-
nificantly greater increase inEes in response toTNF-a stimulation. (D)The change in themaximum rateof developed pressure (DdP/dtmax)wasalsohigher
in WT mice (n ¼ 7–10, *P, 0.05).
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between different components of the TNFRC (TNFR1, TRAF2, and
TRADD) and RASSF1A in the presence of 10 ng/mL of TNF-a.
Results shown in Figure 3C revealed that endogenous RASSF1A
co-precipitated with TNFR1, TRAF2, and TRADD in cardiomyocytes
in the presence of TNF-a. These data strongly suggested that upon
TNF-a stimulation RASSF1A was recruited to the TNFRC, where it
might play an important role as an adapter molecule which links
TRAF2 and TRADD to TNFR1.
TNF-a receptor 2 (TNFR2) has been described to have a protective
role in the heart.21 Therefore, it is important to examine whether
TNFR2 is also involved in the RASSF1A-dependent TNF-a regulation.
However, immunoprecipitation analysis showed that RASSF1A did
not interact with TNFR2 (Figure 3C). This suggests that the RASSF1A
regulatory mechanism was unlikely via TNFR2.
3.5 RASSF1A interacts with TRAF2
and TRADD via its C-terminal end
To further define the mechanism by which RASSF1A modulates
TRAF2 and TRADD recruitment to TNFR1, we performed co-immuno-
precipitation analysis using deletion mutants of the RASSF1A protein as
described previously.15 In brief, we have generated: (i) RASSF1A-DN,
which has the N-terminal region (amino acids 1–132) deleted;
(ii) RASSF1A-DC mutant, which lacks 53 amino acids at the carboxy
terminal region, thereby removing the Salvador-RASSF-Hippo
(SARAH) domain; and (iii) RASSF1A-DC + RA, which lacks both the
RA (Ras binding) and SARAH domains (see Supplementary material
online, Figure S2). We generated adenoviruses to enable expression of
these mutant proteins in neonatal rat cardiomyocytes, which was con-
firmed by western blot (Figure 3D). Immunoprecipitation experiments
showed that only the RASSF1A-DN co-precipitated with TRAF2 and
TRADD. Both of the C-terminal deletion RASSF1A mutants did not
bind to either TRAF2 or TRADD, indicating that the C-terminal
region of RASSF1A is likely to be important in mediating interaction
with both TRAF2 and TRADD (Figure 3E and F ).
3.6 RASSF1A gene silencing in
cardiomyocytes reduces TRAF2 and
TRADD recruitment to TNFR
The phenotype described in Figure 3A and B was the result of systemic
RASSF1A knockout in mice. To assess the effects of acute inactiva-
tion of RASSF1A, we performed a RNAi gene silencing approach.
Adenovirus expressing RASSF1A shRNA was used to effectively
knockdown RASSF1A expression in cardiomyocytes (Figure 4A).
We then performed analyses to assess whether RASSF1A acute gene
silencing altered the interaction between TNFR1 and TRAF2/TRADD.
Co-immunoprecipitation experiments presented in Figure 4B showed
that RASSF1A gene silencing markedly reduced TRAF2 and TRADD re-
cruitment to TNFR1, demonstrating a consistent phenotype between
systemic gene ablation in mice and acute gene silencing using the
RNAi approach in isolated myocytes.
3.7 RASSF1A regulates NFkB activation
in cardiomyocytes
TNF-a regulates several important signalling pathways in cardiomyo-
cytes, such as the NFkB pathway, through binding to the TNFRs.22
To investigate whether alteration of RASSF1A expression modifies
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NF-kB signalling, we performed experiments using adenoviral-mediated
NF-kB luciferase reporter. Using this system, we were able to detect
activation of the NF-kB pathway in response to TNF-a in control
cells. We found a significantly lower NF-kB luciferase activity in cardio-
myocytes lacking RASSF1A following TNF-a treatment (Figure 4C).
Importantly, overexpressing human RASSF1A in cells lacking this
Figure 2 Effect of acute TNF-a or isopretorenol stimulation on calcium transients in isolated adult cardiomyocytes from RASSF1A2/2 mice and WT
littermates. (A) Representative calcium transient traces from WT and RASSF1A2/2 cardiomyocytes loaded with Indo-1 dye before (black line) and after
stimulation with TNF-a (10 ng/mL) for 30 min (red line). (B) Quantification of calcium transient amplitude showed that WT myocytes displayed higher
amplitude following TNF-a treatment compared with RASSF1A2/2 cardiomyocytes. *Two-way ANOVAs showed a significant interaction between
two factors tested (genotype vs. TNF-a, n ¼ 22–24 myocytes from four independent animals in each group). (C) However, no difference in time constant
of calcium decay (Tau) was observed between WT and RASSF1A2/2 both basally or after TNF-a stimulation. (D) Representative calcium transients in
response to b-adrenergic agonist isoproterenol (Iso; 100 nM) in WT and RASSF1A2/2 cardiomyocytes. (E) Quantification of calcium amplitude and
(F) Tau. #Two-way ANOVAs indicated that there was significant effect of Iso treatment but there is no significant interaction between genotype and
Iso response, suggesting that there is no difference in b-adrenergic response between WT and RASSF1A2/2 cardiomyocytes (n ¼ 20–24 myocytes
from four independent animals in each group). *Post hoc multiple comparison test suggested that there were significant differences before and after Iso
treatment in each group.
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Figure3 RASSF1A plays a key role in the recruitment of TRAF2 and TRADD to the TNFRC. (A) Isolated adult cardiomyocytes from RASSF1A2/2mice
and WT littermates were treated with 10 ng/mL of TNF-a for 30 min. Immunoprecipitation analysis indicated a marked reduction of TRADD and (B)
TRAF2 co-precipitation with TNFR1 in RASSF1A2/2 cardiomyocytes compared with WT (n ¼ 4 independent animals). (C ) Immunoprecipitation analysis
of neonatal rat cardiomyocytes (NRCMs) treated with 10 ng/mL of TNF-a. Total protein lysates were precipitated using antibodies as indicated in the
figure. Western blot analyses showed that RASSF1A co-precipitated with TNFR1, TRADD, and TRAF2. However, RASSF1A did not interact with
TNFR2. (D) Overexpression of RASSF1A deletion constructs in NRCM using adenoviral constructs. Expression was detected using an anti-Flag antibody
and GAPDHas a loading control in total protein lysates. (E) Immunoprecipitationanalysis showed thatonlyRASSF1A-DNwasco-precipitated with TRAF2.
Both theDC andDC+RA constructs did not co-precipitate with TRAF2, suggesting that the C-terminal domain of RASSF1A was responsible for binding
with TRAF2. (F ) Similarly, the C-terminal region was also important in mediating interaction with TRADD (n ¼ 3 independent experiments).
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Figure 4 RASSF1A gene knockdown using shRNA reduces the formation of TNFRC and the activation of NFkB pathway. (A) Western blot analysis
showed ablation of RASSF1A expression in NRCM treated with Ad-shRASSF1A. (B) Immunoprecipitation experiments suggested a significant reduction
in the interaction between TNFR1–TRAF2 and TNFR1–TRADD in NRCM treated with Ad-shRASSF1A. All cells were stimulated with 10 ng/mL of
TNF-a. (C) Activation of the NFkB pathway was assessed using adenoviral-driven NFkB-luciferase construct. RASSF1A gene inactivation significantly
reduced NFkB activation in response to TNF-a induction. This phenotype was restored by overexpression of human RASSF1A (*P, 0.05, n ¼ 3 inde-
pendent experiments).
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molecule rescued the NF-kB luciferase activation to the same level as
control cells (Figure 4C). These data strongly support the notion of the
important regulatory role of RASSF1A in TNF-a signalling.
3.8 RASSF1A is essential in regulating
downstream TNF-a signalling
Two possible downstream effectors of the TNF-a signalling pathway
were investigated to gain mechanistic insights into the regulation of car-
diomyocyte calcium dynamics, i.e. the cPLA2 and the CaMKII. We iso-
lated adult cardiomyocytes from RASSF1A2/2 and WT mice and
treated them with 10 ng/mL of TNF-a for 30 min. Measurement of
cPLA2 and CaMKII activities showed that the activities of both
enzymes were significantly increased in response to TNF-a treatment;
however, only cPLA2 activity was markedly reduced in RASSF1A-
deficient cardiomyocytes (Figure 5A and Supplementary material
online, Figure S3), suggesting that cPLA2 was likely the downstream ef-
fector of RASSF1A signalling. In cardiomyocytes, cPLA2 activation will
enhance the formation of arachidonic acid (AA),7 which may eventually
modulate intracellular calcium via a variety of systems, including ion
channel activation and induction of protein kinase A (PKA) activity.23,24
Consistently, PKA activity was significantly reduced in RASSF1A2/2 car-
diomyocytes following TNF-a induction (Figure 5B).
Next, we analysed activation of calcium handling proteins that are es-
sential in regulating calcium transient amplitude. We focused on meas-
uring the phosphorylation levels of L-type calcium channel (LTCC)
and ryanodine receptor (RYR). Western blot analysis showed that
TNF-a stimulation significantly increased the phosphorylation of
LTCC and RYR in WT cardiomyocytes; however, this effect was com-
pletely ablated in RASSF1A2/2 cardiomyocytes (Figure 5C and D).
To further ascertain if RASSF1A regulates TNF-a-dependent calcium
transients via cPLA2, we performed analysis using cPLA2 inhibitor
(AACOCF3, 20 mM) as well as cPLA2 activator peptide (PLAP, 1 mM).
Analysis of calcium transients in WT and RASSF1A2/2 cardiomyocytes
revealed that treatment with AACOCF3 reduced the TNF-a-induced
elevation of Ca2+ transient amplitude in WT myocytes to a level com-
parable with that produced by RASSF1A2/2 myocytes (Figure 6A and B).
No further effect of cPLA2 inhibition was observed in RASSF1A2/2
myocytes. On the other hand, cPLA2 activator was able to rescue
the reduction of TNF-a-induced elevation of Ca2+ transient amplitude
in RASSF1A2/2myocytes (Figure 6A andB). No differencewas observed
in calcium decay rate between WT and RASSF1A2/2 after cPLA2 in-
hibition or activation (Figure 6C). Moreover, inhibition of cPLA2
reduced phosphorylation of LTCC and RYR following TNF-a
treatment in WT cardiomyocytes, whereas treatment with PLAP
rescued the reduction in LTCC and RYR phosphorylation as well as
the reduction in PKA activity in the RASSF1A2/2 cardiomyocytes
(Figure 5A–D).
Taken together, our results suggest that the downstream mechanism
by which RASSF1A affects TNF-a contractile response is likely through
cPLA2 and subsequently the phosphorylation of calcium handling pro-
teins such as RYR and LTCC; via activation of PKA (Figure 6D).
3.9 RASSF1A is involved in the regulation
of lipopolysaccharide-induced contractile
dysfunction
Endotoxemia is an important pathophysiological condition affecting
cardiac contractile function. TNF-a is one of the key mediators of sys-
temic endotoxemia.10 We therefore studied whether RASSF1A is
involved in this process. To model systemic endotoxemia in mice, a
single bolus of bacterial lipopolysaccharide (LPS, 20 mg/kg BW) was
injected intraperitoneally. Cardiac function and serum TNF-a level
were assessed 16 h after injection.
The levels of serum TNF-a were massively increased following LPS
injection; however, we did not observe any difference between WT
and RASSF1A2/2 mice (Figure 7A). Haemodynamic analysis showed
that LPS-treated RASSF1A2/2 mice exhibited a significantly lower con-
tractile function compared with LPS-treated WT mice as indicated by
Ees, dP/dtmax, and dP/dtmin values (Figure 7B–D). We then treated
isolated adult cardiomyocytes from WT and knockout mice with LPS
(10 mg/mL) for 60 min and analysed the calcium transients (Figure 7E–G).
We found that there was no significant difference regarding the change
in calcium amplitude as well as the rate of calcium decay following
direct LPS treatment between WT and RASSF1A2/2 cardiomyocytes.
Furthermore, there was no difference in cPLA2 and PKA activities
between WT and RASSF1A2/2 cardiomyocytes (see Supplementary
material online, Figure S4A and B). Consistently, western blot analysis
suggested that the levels of LTCC and RYR phosphorylation were not
altered in RASSF1A2/2 cardiomyocytes following direct LPS treatment
(see Supplementary material online, Figure S4C and D). We also per-
formed immunoprecipitation analysis to assess whether RASSF1A inter-
acts with LPS receptor, Toll-like receptor 4 (TLR4) in cardiomyocytes.
We found that RASSF1A did not co-precipitate with TLR4 in the cardi-
omyocytes (Figure 7H). Taken together, our data suggest that the differ-
ence in the in vivo contractility was unlikely due to the direct LPS effect on
cardiomyocytes.
4. Discussion
Our study shows that RASSF1A is anessential component for the forma-
tion of the TNFRC in cardiomyocytes and its subsequent downstream
positive inotropic effects. We found that RASSF1A is a key adaptor mol-
ecule that facilitates the recruitment of TRAF2 and TRADD to the
TNFR1 upon TNF-a stimulation, and this process is important in the
regulation of downstream signal transmission. In the absence of RASSF1A,
little if any TRAF2 and TRADD are recruited to the TNFRC. Functionally,
the absence of RASSF1A virtually ablates the contractile response to
TNF-a. Importantly, the b-adrenergic inotropic response was not altered
in RASSF1A2/2 cardiomyocytes, suggesting that the effect of RASSF1A
ablation seems to be specific to TNF-a signalling.
Previous reports have shown that acute application of low doses of
TNF-a produces an increase in calcium transient amplitude and
cardiac contractility.8,9 In RASSF1A2/2 mice and adult cardiomyocytes
isolated from RASSF1A2/2, these effects were abolished. We proposed
that RASSF1A facilitates the association of TRAF2 and TRADD, two
molecules essential for TNF signalling, with the TNFRC. In the
absence of RASSF1A, less TRAF2 and TRADD were recruited to the
complex upon stimulation with TNF-a, leading to a reduction in down-
stream phospholipase-mediated signal transmission and hence a reduc-
tion in the calcium amplitude and contractility. Previously, it has been
described that the N-terminus of RASSF1A is responsible for the inter-
action with TNFR120 in the U2OS osteosarcoma cell line. In this study,
we show the interaction of RASSF1A with TRAF2 and TRADD, which is
likely mediated by the C-terminal region of RASSF1A. Therefore, we
speculate that, in the process of TNFRC formation, RASSF1A may act
as an adaptor molecule linking TRAF2/TRADD (via its C-terminal
domain) to TNFR1 (via its N-terminal domain).
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In various cell types, including cardiomyocytes, TNF-a stimulation
induces cPLA2 activation.25 It has been shown previously that cPLA2 ac-
tivation requires phosphorylation by p38 and caspase-mediated cleav-
age for its activation.26,27 TRAF2 is important in the TNFa-induced
p38 phosphorylation via receptor-interacting protein and germinal
centre kinase,28 whereas TRADD is crucial in the TNFa-induced
caspase activation.29 Further downstream, active cPLA2 induces the
release of AA from the cell membrane and hence elevation of AA
level.25 AA has the capability to induce calcium entry from the intracel-
lular calcium store.23 This process is dependent on PKA and anchoring
protein for PKA (AKAP) activities, since inhibition of PKA30 and disrup-
tion of AKAP function23 abolish AA-induced calcium release. Taken
together, these reports suggest that cPLA2 may activate PKA via AA
and AKAP may play an important role in the spatial regulation of this
signal.
Another possible downstream effector of TNF-a stimulation is
CaMKII. Although as expected we observed significant elevation of
CaMKII activity following TNF-a stimulation, we did not find any differ-
encebetween WTandRASSF1A2/2 cardiomyocytes. This suggests that
the TNF-a-induced CaMKII activation is unlikely to be mediated by the
RASSF1A-dependent pathway. Indeed, it has been shown that the
TNF-a-induced CaMKII activation is mostly mediated by oxidation
and autophosphorylation processes due to the elevation of free radi-
cals.31,32 This might explain our finding that the CaMKII activation was
not different between WT and RASSF1A2/2 cardiomyocytes.
In this study, we found that ablation of RASSF1A led to the reduction
in cPLA2 activity as well as decreased phosphorylation of major calcium
handling proteins, such as LTCC and RYR, following TNF-a stimulation.
In fact, cPLA2 inhibition using AACOCF3 abolished the TNF-a-induced
inotropic response (elevation of intracellular Ca2+ amplitude) as well as
Figure 5 RASSF1A regulates cPLA2 activation and phosphorylation of calcium handling molecules. (A) cPLA2 activity was measured in isolated adult
cardiomyocytes from RASSF1A2/2 mice and WT littermates treated with 10 ng/mL of TNF-a for 30 min. (*P, 0.05, n ¼ 7–8) with or without the add-
ition of cPLA2 activator peptide (PLAP; 1 mM) or cPLA2 inhibitor (AACOCF3; 20 mM). (B) PKA activity was significantly lower in RASSF1A2/2 cardio-
myocytes following treatment with TNF-a (*P, 0.05, n ¼ 7–8). Treatment with cPLA2 activator rescued the reduction of PKA activity in
RASSF1A2/2 cardiomyocytes, whereas cPLA2 inhibitor reduced PKA activity of WT to the level similar with RASSF1A2/2. Western blot and band
density measurement of (C) phosphorylated/total LTCC and (D) phosphorylated/total RYR showed a significant reduction in phosphorylation of
LTCC and RYR in RASSF1A2/2 cardiomyocytes following TNF-a treatment. Treatment with cPLA inhibitor AACOCF3 (20 mM) abolished LTCC and
RYR phosphorylation in WT cells to the level comparable with RASSF1A2/2 myocytes, whereas cPLA2 activator (PLAP; dose) rescued the phenotype
of RASSF1A2/2 cardiomyocytes (*P, 0.05, n ¼ 6–8).
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the phosphorylation of LTCC and RYR in WT cardiomyocytes, whereas
treatment with cPLA2 activator (PLAP) rescued the phenotype of
RASSF1A2/2 myocytes. Taken together, our data present one possible
mechanism explaining the reduction in contractile response and calcium
transients in RASSF1A2/2 cardiomyocytes following TNF-a stimula-
tion: ablation of RASSF1A alters the formation of the TNFRC, in particu-
lar the recruitment and activation of TRAF2 and TRADD, which
subsequently causes a reduction in cPLA2 activation. This will result in
the decreased activity of the downstream effectors, possibly PKA,
which will eventually lead to the reduction in LTCC and RYR
phosphorylation.
Previouspublications have reported that RASSF1A acts as an inhibitor
of NFkB signalling in fibroblasts33 and colon epithelium.34 This may
suggest a cell-specific function of RASSF1A, since our observation sug-
gests that, in cardiomyocytes, RASSF1A facilitates signal transmission
from TNFR1 to the downstream targets including NFkB. It is also im-
portant to note that in the previous reports NFkB signal was assessed
in unstimulated fibroblasts33 or in LPS-stimulated colon epithelium,34
Figure 6 Effects of cPLA2 inhibition and activation on TNF-a induced calcium transients. (A) Representative calcium transient traces from WT and
RASSF1A2/2 adult cardiomyocytes loaded with Indo-1 dye at basal and after stimulation with TNF-a (10 ng/mL) for 30 min in the presence of cPLA2
activatorpeptide (PLAP; 1 mM ,blue line) orcPLA2 inhibitor (AACOCF3, 20 mM, red line). (B) Analysisof calcium transient amplitude and (C) time constant
of calcium decay (Tau) indicated that inhibition of cPLA2 abolished the TNF-a-induced elevation of calcium transient in WT cardiomyocytes, whereas
cPLA2 rescued the reduction of TNF-a-induced contractile response in RASSF1A2/2 myocytes as shown in Figure 2 (n ¼ 25–30 cells in each group
taken from four animals). (D) Schematic diagram of possible downstream signalling pathway regulated by RASSF1A.
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whereas in the present observation we used TNF-a to stimulate
cardiomyocytes.
While we found a strong association between RASSF1A, TNFR1, and
its molecular complex, we did not observe interaction between
RASSF1A and TNFR2. Although a previous publication has shown the
involvement of TNFR2 in modulating cPLA2 activity,35 it is known that
soluble TNF-a is inefficient in activating TNFR2,36 and hence treatment
with soluble TNF-a will mainly activate TNFR1.37 This might be an ex-
planation for our finding that RASSF1A2/2 displayed a completely atte-
nuated response to TNF-a, since we treated cardiomyocytes with
soluble TNF-a and hence there was no response of TNFR2. Another
possible explanation is related to the signalling crosstalk between
TNFR1 and TNFR2. It has been described that these receptors can influ-
ence each other’s functions, for example, TNFR2 function might be de-
pendent on TNFR1 since signalling via TNFR1 is required for the
expression of several molecules which are important in mediating
TNFR2 function, such as TRAF1 and cIAP1.38 It is possible therefore
that, in RASSF1A2/2 myocytes, TNFR2 was indirectly inhibited as a
result of reduced TNFR1 signalling. Indeed, further studies need to be
performed to address the role of RASSF1A in TNFR2 signalling.
Figure 7 In vivo cardiac contractility following LPS infusion. (A) Serum TNF-a level was markedly elevated following treatment with LPS (20 mg/kg BW)
for 16 h. #Two-way ANOVAs indicated that therewasa significant effect of LPS, but therewasno significant interaction between genotype and TNF-a level.
*Post hocmultiple comparison test showed that there was a significant difference in TNF-a levels between the LPS and non-LPS group (P, 0.05). (B) Ana-
lysis of Ees values, (C ) dP/dtmax, and (D) dP/dtmin in mice after LPS treatment. *Two-way ANOVAs showed that there was a significant effect of LPS treat-
ment and interaction between two factors tested (genotype vs. LPS). ##Post hoc multiple comparison showed that RASSF1A2/2 mice exhibited a
significantly lower contractility compared with WT (n ¼ 5–6 per group). (E) Representative calcium transients in response to LPS stimulation (10 mg/
mL, 60 min) in WT and RASSF1A2/2 adult cardiomyocytes. (F) Quantification of calcium amplitude and (G) Tau. Two-way ANOVAs indicated that
there was no significant interaction between genotype and treatment. (F ) Immunoprecipitation analysis of isolated WT cardiomyocytes showed that
RASSF1A did not interact with TLR4 in cardiomyocytes.
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RASSF1A also forms complex with other membrane molecules,
notably the plasma membrane calcium ATPase 4 (PMCA4).39 PMCA4
is a calcium extrusion pump which is located in the caveolae.40 Since
TNFR1 is also enriched in the caveolae,41 it is possible that PMCA4 is
involved in the regulation of TNFR1 signalling, although further studies
need to be done to test this idea.
The present study also provides initial evidence of the possible in-
volvement of RASSF1A in LPS-induced cardiomyopathy. In response
to LPS injection, RASSF1A2/2 mice displayed a significant decrease in
contractility compared with WTs. Interestingly, no differences in Ca2+
amplitude, cPLA2, and PKA activities or phosphorylation of LTCC and
RYR were observed when we directly challenged isolated cardiomyo-
cytes with LPS. Also, we found that RASSF1A did not interact with
TLR4 in cardiomyocytes. Therefore, we speculated that this phenotype
might be caused by the different response to TNF-a signalling. Both WT
and RASSF1A2/2 mice produced comparable levels of TNF-a in the
serum following LPS injection; however, since RASSF1A2/2mice exhib-
ited an attenuated inotropic response to TNF-a, this could account for
the reduced contractility exhibited by RASSF1A2/2 mice following LPS
injection (see Supplementary material online, Figure S5). It should be
noted that further experiments need to be done to clarify the exact
mechanism by which RASSF1A modulates LPS-induced cardiomyop-
athy. For example, a rescue experiment by activating the cPLA2–PKA
pathway in RASSF1A2/2 mice during LPS stimulation is needed to elu-
cidate whether this pathway is responsible in mediating the observed
phenotype.
In summary, our present work demonstrates a novel TNF-a effector
pathway mediated by RASSF1A which transmits the positive inotropic
effect of TNF-a in cardiomyocytes. The complete understanding of
the effector pathways of TNF-a is pivotal that may enable us to
develop molecules that preserve the beneficial effect of TNF-a in the
heart. This could be very useful for the treatment of conditions involving
acute TNF-a elevation such as endotoxemia.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
Conflict of interest: none declared.
Funding
This work was supported by British Heart Foundation (BHF) Intermediate
Fellowship Grant (FS/09/046/28043) and BHF Project Grant (PG/11/23/
28801) to D.O, and a Medical Research Council (MRC) Research Grant
(G0802004) to L.N.
References
1. Kadokami T, McTiernan CF, Kubota T, Frye CS, Feldman AM. Sex-related survival differ-
ences in murine cardiomyopathy are associated with differences in TNF-receptor ex-
pression. J Clin Invest 2000;106:589–597.
2. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ,
Feldman AM. Dilated cardiomyopathy in transgenic mice with cardiac-specific overex-
pression of tumor necrosis factor-alpha. Circ Res 1997;81:627–635.
3. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, Feldman AM. Myo-
cardial extracellular matrix remodeling in transgenic mice overexpressing tumor necro-
sis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl
Acad Sci USA 2000;97:12746–12751.
4. London B, Baker LC, Lee JS, Shusterman V, Choi BR, Kubota T, McTiernan CF,
Feldman AM, Salama G. Calcium-dependent arrhythmias in transgenic mice with heart
failure. Am J Physiol Heart Circ Physiol 2003;284:H431–H441.
5. Nakano M, Knowlton AA, Dibbs Z, Mann DL. Tumor necrosis factor-alpha confers re-
sistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation 1998;97:
1392–1400.
6. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor ne-
crosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes.
Circulation 1997;95:1247–1252.
7. Murray DR, Freeman GL. Tumor necrosis factor-alpha induces a biphasic effect on myo-
cardial contractility in conscious dogs. Circ Res 1996;78:154–160.
8. Amadou A, Nawrocki A, Best-Belpomme M, Pavoine C, Pecker F. Arachidonic acid med-
iatesdual effect of TNF-alpha on Ca2+ transients and contraction of adult rat cardiomyo-
cytes. Am J Physiol Cell Physiol 2002;282:C1339–C1347.
9. Cailleret M, Amadou A, Andrieu-Abadie N, Nawrocki A, Adamy C, Ait-Mamar B,
Rocaries F, Best-Belpomme M, Levade T, Pavoine C, Pecker F.N-acetylcysteine prevents
the deleterious effect of tumor necrosis factor-(alpha) on calcium transients and con-
traction in adult rat cardiomyocytes. Circulation 2004;109:406–411.
10. Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ. Acute renal failure in
endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol
2002;168:5817–5823.
11. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and func-
tional significance of tumor necrosis factor receptors in human myocardium. Circulation
1995;92:1487–1493.
12. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002;296:
1634–1635.
13. Avruch J, Xavier R, Bardeesy N, Zhang XF, Praskova M, Zhou D, Xia F. Rassf family of
tumor suppressor polypeptides. J Biol Chem 2009;284:11001–11005.
14. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007;120:
3163–3172.
15. Oceandy D, Pickard A, Prehar S, Zi M, Mohamed TM, Stanley PJ, Baudoin-Stanley F,
Nadif R, Tommasi S, Pfeifer GP, Armesilla AL, Cartwright EJ, Neyses L. Tumor suppres-
sor Ras-association domain family 1 isoform A is a novel regulator of cardiac hyper-
trophy. Circulation 2009;120:607–616.
16. Chadee DN, Yuasa T, Kyriakis JM. Direct activation of mitogen-activated protein kinase
kinase kinase MEKK1 by the Ste20p homologue GCK and the adapter protein TRAF2.
Mol Cell Biol 2002;22:737–749.
17. Tommasi S, Dammann R, Zhang Z, Wang Y, Liu L, Tsark WM, Wilczynski SP, Li J, You M,
Pfeifer GP. Tumor susceptibility of Rassf1a knockout mice. Cancer Res 2005;65:92–98.
18. Mohamed TM, Oceandy D, Zi M, Prehar S, Alatwi N, Wang Y, Shaheen MA,
Abou-Leisa R, Schelcher C, Hegab Z, Baudoin F, Emerson M, Mamas M, Di
Benedetto G, Zaccolo M, Lei M, Cartwright EJ, Neyses L. Plasma membrane calcium
pump (PMCA4)-neuronal nitric-oxide synthase complex regulates cardiac contractility
through modulation of a compartmentalized cyclic nucleotide microdomain. J Biol Chem
2011;286:41520–41529.
19. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated
by TNF superfamily. Cytokine Growth Factor Rev 2003;14:193–209.
20. Foley CJ, Freedman H, Choo SL, Onyskiw C, Fu NY, Yu VC, Tuszynski J, Pratt JC, Baksh S.
Dynamics of RASSF1A/MOAP-1 association with death receptors.Mol Cell Biol 2008;28:
4520–4535.
21. Burchfield JS, Dong JW, Sakata Y, Gao F, Tzeng HP, Topkara VK, Entman ML,
Sivasubramanian N, Mann DL. The cytoprotective effects of tumor necrosis factor are
conveyed through tumor necrosis factor receptor-associated factor 2 in the heart.
Circ Heart Fail 2010;3:157–164.
22. Cao Z, Tanaka M, Regnier C, Rothe M, Yamit-hezi A, Woronicz JD, Fuentes ME,
Durnin MH, Dalrymple SA, Goeddel DV. NF-kappa B activation by tumor necrosis
factor and interleukin-1. Cold Spring Harb Symp Quant Biol 1999;64:473–483.
23. Saino T, Watson EL. Inhibition of serine/threonine phosphatase enhances arachidonic
acid-induced [Ca2+]i via protein kinase A. Am J Physiol Cell Physiol 2009;296:C88–C96.
24. VanBilsen M, Vander Vusse GJ. Phospholipase-A2-dependent signalling in the heart.Car-
diovasc Res 1995;30:518–529.
25. Liu SJ, McHowat J. Stimulation of different phospholipase A2 isoforms by TNF-alpha and
IL-1beta in adult rat ventricular myocytes. Am J Physiol 1998;275:H1462–H1472.
26. Waterman WH, Molski TF, Huang CK, Adams JL, Sha’afi RI. Tumour necrosis
factor-alpha-induced phosphorylation and activation of cytosolic phospholipase A2
are abrogated by an inhibitor of the p38 mitogen-activated protein kinase cascade in
human neutrophils. Biochem J 1996;319(Pt 1):17–20.
27. Wissing D, Mouritzen H, Egeblad M, Poirier GG, Jaattela M. Involvement of caspase-
dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced
apoptosis. Proc Natl Acad Sci USA 1997;94:5073–5077.
28. Yuasa T, Ohno S, Kehrl JH, Kyriakis JM. Tumor necrosis factor signaling to
stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) and p38. Germi-
nal center kinase couples TRAF2 to mitogen-activated protein kinase/ERK kinase kinase
1 and SAPK while receptor interacting protein associates with a mitogen-activated
protein kinase kinase kinase upstream of MKK6 and p38. J Biol Chem 1998;273:
22681–22692.
29. Bender LM, Morgan MJ, Thomas LR, Liu ZG, Thorburn A. The adaptor protein TRADD
activates distinct mechanisms of apoptosis from the nucleus and the cytoplasm. Cell
Death Differ 2005;12:473–481.
30. FiorioPla A,GenovaT, Pupo E, Tomatis C,Genazzani A, Zaninetti R,MunaronL.Multiple
roles of protein kinase A in arachidonic acid-mediated Ca2+ entry and tumor-derived
human endothelial cell migration. Mol Cancer Res 2010;8:1466–1476.
31. Scott JA, Xie L, Li H, Li W, He JB, Sanders PN, Carter AB, Backs J, Anderson ME,
Grumbach IM. The multifunctional Ca2+/calmodulin-dependent kinase II regulates
T.M.A. Mohamed et al.58
by guest on June 7, 2016
D
ow
nloaded from
 
vascular smooth muscle migration throughmatrix metalloproteinase 9.Am JPhysiolHeart
Circ Physiol 2012;302:H1953–H1964.
32. Zhu LJ, Klutho PJ, Scott JA, Xie L, Luczak ED, Dibbern ME, Prasad AM, Jaffer OA,
Venema AN, Nguyen EK, Guan X, Anderson ME, Grumbach IM. Oxidative activation
of the Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) regulates vascular
smooth muscle migration and apoptosis. Vascul Pharmacol 2014;60:75–83.
33. Del Re DP, Matsuda T, Zhai P, Gao S, Clark GJ, Van Der Weyden L, Sadoshima J. Proa-
poptotic Rassf1A/Mst1signaling in cardiacfibroblasts is protective againstpressure over-
load in mice. J Clin Invest 2010;120:3555–3567.
34. Gordon M, El-Kalla M, Zhao Y, Fiteih Y, Law J, VolodkoN, Mohamed A, El-Kadi AO, Liu L,
Odenbach J, Thiesen A, Onyskiw C, Ghazaleh HA, Park J, Lee SB, Yu VC,
Fernandez-Patron C, Alexander RT, Wine E, Baksh S. The tumor suppressor gene,
RASSF1A, is essential for protection against inflammation-induced injury. PLoS ONE
2013;8:e75483.
35. Defer N, Azroyan A, Pecker F, Pavoine C. TNFR1 and TNFR2 signaling interplay in
cardiac myocytes. J Biol Chem 2007;282:35564–35573.
36. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S,
Lesslauer W, Kollias G, Pfizenmaier K, Scheurich P. The transmembrane form of
tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis
factor receptor. Cell 1995;83:793–802.
37. Jupp OJ, Vandenabeele P, MacEwan DJ. Distinct regulation of cytosolic phospholipase A2
phosphorylation, translocation, proteolysis and activation by tumour necrosis factor-
receptor subtypes. Biochem J 2003;374:453–461.
38. Naude PJ, den Boer JA, Luiten PG, Eisel UL. Tumor necrosis factor receptor cross-talk.
FEBS J 2011;278:888–898.
39. Armesilla AL, Williams JC, Buch MH, Pickard A, Emerson M, Cartwright EJ, Oceandy D,
Vos MD, Gillies S, Clark GJ, Neyses L. Novel functional interaction between the plasma
membrane Ca2+ pump 4b and the proapoptotic tumor suppressor Ras-associated
factor 1 (RASSF1). J Biol Chem 2004;279:31318–31328.
40. Mohamed TM, Abou-LeisaR, Baudoin F, StaffordN, NeysesL, Cartwright EJ,OceandyD.
Development and characterization of a novel fluorescent indicator protein
PMCA4-GCaMP2 in cardiomyocytes. J Mol Cell Cardiol 2013;63:57–68.
41. D’Alessio A, Al-Lamki RS, Bradley JR, Pober JS. Caveolae participate in tumor necrosis
factor receptor 1 signaling and internalization in a human endothelial cell line. Am J
Pathol 2005;166:1273–1282.
Role of RASSF1A in TNF-a signalling 59
by guest on June 7, 2016
D
ow
nloaded from
 
